Intracellular Delivery of the p38 Mitogen-Activated Protein Kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1 H-imidazole] in Renal Tubular Cells: A Novel Strategy to Treat Renal FibrosisJai Prakash, Robbert J. Kok, Klaas Poelstra et al.|Journal of Pharmacology and Experimental Therapeutics|2006Cited by 57
Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labelingRobbert J. Kok, Dirk K. F. Meijer, Dick de Zeeuw et al.|Journal of Chromatography B Biomedical Sciences and Applications|1997Cited by 56
Cell-specific Delivery of a Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor to Proximal Tubular Cells for the Treatment of Renal FibrosisJai Prakash, Robbert J. Kok, Martin H. de Borst et al.|Pharmaceutical Research|2008Cited by 46
Specific Delivery of Captopril to the Kidney with the Prodrug Captopril-LysozymeRobbert J. Kok, Dirk K. F. Meijer, Frits Moolenaar et al.|Journal of Pharmacology and Experimental Therapeutics|1999Cited by 37
Drug Delivery to the Kidneys and the Bladder with the Low Molecular Weight Protein LysozymeRobbert J. Kok, Dirk Meijer, Marijke Haas et al.|Renal Failure|1998Cited by 25